Meclofenoxate

Meclofenoxate is an ester formed from dimethylethanolamine (DMAE), a compound related to the neurotransmitter precursor choline, and 4-chlorophenoxyacetic acid. After it is taken, the ester is thought to break down and deliver DMAE, which is regarded as the main active portion ^[4]. It was introduced around 1959 and has been marketed under names such as Lucidril and Cerebron, and in several countries it is a prescription medicine for cognitive impairment in the elderly, while in the United States it is not approved as a drug and is instead sold, questionably, as a dietary supplement ^[4].

Interest in meclofenoxate has centered on cognition and brain aging. An early double-blind study in healthy elderly people found that it improved the consolidation of new information into long-term memory and increased self-reported mental alertness, without broadly enhancing every aspect of memory ^[1]. Comparative clinical trials in patients with Alzheimer-type senile dementia reported improvements in cognitive performance with meclofenoxate, although in those studies a multi-ingredient formula containing it performed even better ^[3]. Much of the human evidence is decades old and comes from small trials, so it is considered limited by modern standards ^[1][3].

A distinctive theme in the literature is the compound's proposed anti-aging and antioxidant activity. It has been studied for its ability to reduce lipofuscin, a pigment that builds up in aging cells, and animal work has reported protective effects on neurons. In a rat model of chronic reduced blood flow to the brain, centrophenoxine improved memory performance and lessened neuronal degeneration, effects linked to reduced oxidative stress and inflammatory markers ^[2]. These findings are largely preclinical and have not been confirmed as clinical anti-aging benefits ^[2].

Because meclofenoxate is sold in some markets as a supplement despite being an unapproved drug, its regulatory status is inconsistent. An analysis of over-the-counter cognitive-enhancement supplements found centrophenoxine present in products at pharmacologically active amounts, with most labels inaccurately stating the quantity, prompting warnings that such supplements may contain unapproved drugs ^[4]. Where it is a licensed medicine it is used under medical supervision; elsewhere its quality and labeling are not assured ^[4].

Meclofenoxate is generally well tolerated. The usual side effects are nausea, headache, trouble sleeping (if you take it late), irritability, and overstimulation at high doses; most of that is the cholinergic load talking. Avoid it if you're hypersensitive to DMAE or pCPA. Be cautious with bipolar disorder or a history of mania, since too much cholinergic tone can deepen low or dysphoric moods. Don't stack it with anticholinergics (they cancel it out) or pile it onto other heavy cholinergics (acetylcholine overload). It's not really a scheduling concern in most countries, though it's prescription-only in a few (Japan, Germany, Hungary).

Meclofenoxate, also known as centrophenoxine and marketed as Lucidril, was developed in 1959 at France's national scientific research center (Centre National de la Recherche Scientifique). It is an ester combining dimethylaminoethanol (DMAE) with para-chlorophenoxyacetic acid, and it was introduced as a treatment for age-related cognitive decline and organic brain syndromes. Subsequent gerontological research, notably studies of lipofuscin accumulation in aging tissue, drew further attention to its use.

Meclofenoxate holds a long-standing reputation in the nootropic and anti-aging communities as a classic cholinergic and cellular-cleanup agent, prized for reported reductions in the age pigment lipofuscin and for a more brain-targeted delivery of DMAE. Clinicians regard the human evidence as modest and dated, drawn largely from older European trials in dementia and cognitive impairment, so while it is generally considered well tolerated, its standing rests more on decades of anecdotal use and preclinical aging research than on robust modern clinical proof.